NO20035086D0 - Karboksylsyresubstituerte oxazolderivater for anvendelse som PPAR-alfa og gamma-aktivatorer i behandling av diabetes - Google Patents

Karboksylsyresubstituerte oxazolderivater for anvendelse som PPAR-alfa og gamma-aktivatorer i behandling av diabetes

Info

Publication number: NO20035086D0
Authority: NO; Norway
Prior art keywords: ppar; diabetes; alpha; treatment; carboxylic acid
Prior art date: 2001-05-15

Application number

NO20035086A

Other languages

English (en)

Other versions

NO20035086L (no

NO333833B1 (no

Inventor

Alfred Binggeli

Markus Boehringer

Uwe Grether

Hans Hilpert

Hans-Peter Maerki

Markus Meyer

Peter Mohr

Fabienne Ricklin

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-15

Filing date

2003-11-14

Publication date

2003-11-14

2003-11-14 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2003-11-14 Publication of NO20035086L publication Critical patent/NO20035086L/no

2003-11-14 Publication of NO20035086D0 publication Critical patent/NO20035086D0/no

2013-09-30 Publication of NO333833B1 publication Critical patent/NO333833B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20035086A 2001-05-15 2003-11-14 Karboksylsyresubstituerte oksazolderivater, fremgangsmåte for fremstilling av slike, farmasøytiske preparater omfattende slike, slike forbindelser som medikamenter samt slike forbindelser for behandling og/eller forebygging av sykdommer som blir modulert av PPAR-alfa- og/eller PPAR-gamma-agonister NO333833B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01111745		2001-05-15
PCT/EP2002/004962 WO2002092084A1 (en)	2001-05-15	2002-05-06	Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Publications (3)

Publication Number	Publication Date
NO20035086L NO20035086L (no)	2003-11-14
NO20035086D0 true NO20035086D0 (no)	2003-11-14
NO333833B1 NO333833B1 (no)	2013-09-30

Family

ID=8177436

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20035086A NO333833B1 (no)	2001-05-15	2003-11-14	Karboksylsyresubstituerte oksazolderivater, fremgangsmåte for fremstilling av slike, farmasøytiske preparater omfattende slike, slike forbindelser som medikamenter samt slike forbindelser for behandling og/eller forebygging av sykdommer som blir modulert av PPAR-alfa- og/eller PPAR-gamma-agonister

Country Status (38)

Country	Link
US (1)	US6642389B2 (no)
EP (1)	EP1392295B1 (no)
JP (2)	JP4330883B2 (no)
KR (1)	KR100654516B1 (no)
CN (1)	CN100356917C (no)
AR (1)	AR035892A1 (no)
AT (1)	ATE327753T1 (no)
AU (1)	AU2002342244B2 (no)
BG (1)	BG66316B1 (no)
BR (1)	BRPI0209821B1 (no)
CA (1)	CA2445145C (no)
CY (1)	CY1105160T1 (no)
CZ (1)	CZ20033037A3 (no)
DE (1)	DE60211891T2 (no)
DK (1)	DK1392295T3 (no)
EC (1)	ECSP034848A (no)
EG (1)	EG25755A (no)
ES (1)	ES2264482T3 (no)
GT (1)	GT200200085A (no)
HR (1)	HRP20030889B1 (no)
HU (1)	HU230224B1 (no)
IL (2)	IL158589A0 (no)
JO (1)	JO2282B1 (no)
MA (1)	MA27025A1 (no)
ME (1)	ME01310B (no)
MX (1)	MXPA03010435A (no)
MY (1)	MY136761A (no)
NO (1)	NO333833B1 (no)
NZ (1)	NZ529033A (no)
PA (1)	PA8544901A1 (no)
PE (1)	PE20021152A1 (no)
PL (1)	PL208074B1 (no)
PT (1)	PT1392295E (no)
RU (1)	RU2278859C2 (no)
SI (1)	SI1392295T1 (no)
SK (1)	SK287842B6 (no)
WO (1)	WO2002092084A1 (no)
ZA (1)	ZA200308538B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7041691B1 (en)	1999-06-30	2006-05-09	Amgen Inc.	Compounds for the modulation of PPARγ activity
WO2001090087A1 (en) *	2000-05-26	2001-11-29	Nippon Shinyaku Co., Ltd.	Heterocyclic compounds
US20030171399A1 (en)	2000-06-28	2003-09-11	Tularik Inc.	Quinolinyl and benzothiazolyl modulators
MXPA03010435A (es) *	2001-05-15	2004-03-09	Hoffmann La Roche	Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
US7732451B2 (en) *	2001-08-10	2010-06-08	Palatin Technologies, Inc.	Naphthalene-containing melanocortin receptor-specific small molecule
JP2005504043A (ja)	2001-08-10	2005-02-10	パラチンテクノロジーズインク．	生物学的に活性な金属ペプチド類のペプチド模倣体類
US7718802B2 (en)	2001-08-10	2010-05-18	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) *	2003-05-01	2008-11-25	Palatin Technologies Inc.	Melanocortin receptor-specific compounds
US7655658B2 (en) *	2001-08-10	2010-02-02	Palatin Technologies, Inc.	Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
ATE415160T1 (de)	2002-02-25	2008-12-15	Lilly Co Eli	Modulatoren von peroxisome proliferator- aktivierten rezeptoren
MXPA05002115A (es) *	2002-08-30	2005-05-23	Hoffmann La Roche	Compuestos novedosos de 2-ariltiazol como agonistas de pparalfa y ppargama.
AR041481A1 (es)	2002-10-07	2005-05-18	Hoffmann La Roche	Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
HRP20050520A2 (en) *	2002-11-15	2005-10-31	Cadila Healthcare Limited	Substituted aralkyl derivatives
ATE405560T1 (de) *	2002-11-25	2008-09-15	Hoffmann La Roche	Indolderivaten
US7268157B2 (en) *	2002-11-26	2007-09-11	Shenzhen Chipscreen Biosciences, Ltd.	Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr)	2003-01-13	2006-08-04	Merck Sante Sas	Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7968548B2 (en) *	2003-05-01	2011-06-28	Palatin Technologies, Inc.	Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en)	2003-05-01	2010-06-01	Palatin Technologies, Inc.	Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en)	2003-05-01	2010-06-01	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific single acyl piperazine compounds
US7262303B2 (en) *	2003-09-29	2007-08-28	Hoffman-La Roche Inc.	Process for the production of chiral propionic acid derivatives
US7223761B2 (en)	2003-10-03	2007-05-29	Amgen Inc.	Salts and polymorphs of a potent antidiabetic compound
NZ546444A (en)	2003-11-05	2009-09-25	Hoffmann La Roche	Phenyl derivatives as PPAR agonists
KR100849352B1 (ko) *	2003-11-05	2008-07-29	에프. 호프만-라 로슈 아게	Ｐｐａｒ 활성화제로서 벤조-융합된 화합물
WO2005056536A1 (en) *	2003-12-10	2005-06-23	Ranbaxy Laboratories Limited	Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en)	2004-04-19	2010-05-04	Palatin Technologies, Inc.	Substituted melanocortin receptor-specific piperazine compounds
SI1756096T1 (sl)	2004-05-03	2009-10-31	Hoffmann La Roche	Indolilni derivati kot modulatorji jetrnega x receptorja
CN100344618C (zh) *	2004-05-24	2007-10-24	北京摩力克科技有限公司	作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) *	2004-05-24	2008-11-26	北京摩力克科技有限公司	作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
WO2006108491A1 (en) *	2005-04-11	2006-10-19	Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg	Improved process for preparing oxazole nitriles
US20060241073A1 (en) *	2005-04-20	2006-10-26	Wanders Ronaldus J A	Means and methods for counteracting fatty acid accumulation
US7834017B2 (en)	2006-08-11	2010-11-16	Palatin Technologies, Inc.	Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) *	2006-10-26	2008-07-23	재단법인서울대학교산학협력재단	2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
AU2008221718A1 (en) *	2007-03-07	2008-09-12	Dong-A Pharm. Co., Ltd.	Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
DK2100604T3 (da) *	2008-03-10	2012-07-23	Nestec Sa	Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser
WO2009140163A1 (en) *	2008-05-15	2009-11-19	Merck & Co., Inc.	Oxazolobenzimidazole derivatives
CA2747332C (en)	2008-12-23	2015-01-27	F. Hoffmann-La Roche Ag	Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
CA2748896C (en) *	2009-01-23	2017-01-03	F. Hoffmann-La Roche Ag	Pharmaceutical composition comprising aleglitazar
CN101805337B (zh) *	2009-02-13	2012-05-23	天津药物研究院	一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en)	2009-03-24	2013-05-28	Hoffman-La Roche Inc.	Process for the preparation of propionic acid derivatives
CA2783448C (en)	2009-12-07	2018-11-20	F. Hoffmann-La Roche Ag	Process for the preparation of propionic acid derivatives
CN102351852B (zh) *	2011-08-23	2014-06-18	上海交通大学	苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en)	2012-05-31	2013-12-05	Ratiopharm Gmbh	Solid state forms of aleglitazar sodium
JP2015528476A (ja) *	2012-09-12	2015-09-28	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	（Ｓ）−２−メトキシ−３−｛４−［２−（５−メチル−２−フェニル−オキサゾール−４−イル）−エトキシ］−ベンゾ［ｂ］チオフェン−７−イル｝−プロピオン酸の及びその塩の固体形態
CN109588042A (zh)	2015-11-18	2019-04-05	豪夫迈·罗氏有限公司	用于治疗糖尿病肾病的阿格列扎
US20190350955A1 (en)	2016-06-30	2019-11-21	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en)	2019-02-01	2020-08-06	F. Hoffmann-La Roche Ag	Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en)	2019-04-01	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
MX2024001889A (es) *	2021-08-13	2024-02-29	Alebund Pharmaceuticals Hong Kong Ltd	Compuestos deuterados.
AU2023376551A1 (en)	2022-11-08	2025-04-17	Genfit	Ppar-alpha/gamma agonist for use in the treatment of liver failure
CN118480034B (zh) *	2023-02-13	2025-02-11	礼邦医药(香港)有限公司	氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4011326A (en)	1975-07-29	1977-03-08	Merck & Co., Inc.	2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en)	1990-06-14	1992-02-18	Pfizer Inc.	3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) *	1992-05-05	1995-04-10	Бристоль-Мейерз Сквибб Компани	Производные оксазола
DE69331010D1 (de)	1992-07-03	2001-11-29	Smithkline Beecham Plc	Benzoxazol- und benzothiazol-derivate als arzneimittel
GB9225386D0 (en)	1992-12-04	1993-01-27	Smithkline Beecham Plc	Novel compounds
DE4317320A1 (de) *	1993-05-25	1994-12-01	Boehringer Mannheim Gmbh	Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en)	1993-12-22	1994-02-23	Smithkline Beecham Plc	Novel compounds
GB9600464D0 (en)	1996-01-09	1996-03-13	Smithkline Beecham Plc	Novel method
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
JP4290765B2 (ja)	1996-12-10	2009-07-08	ブリストル−マイヤーズスクイブカンパニー	ベンゾジオキソール、ベンゾフラン、ジヒドロベンゾフランおよびベンゾジオキサンメラトニン作用薬
DE19711616A1 (de) *	1997-03-20	1998-09-24	Boehringer Mannheim Gmbh	Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en)	1997-07-14	2000-09-19	Xerox Corporation	Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es)	1997-08-27	1999-02-09	Pfizer Prod Inc	2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es)	1997-09-19	2004-03-01	Ssp Co., Ltd.	Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
EP1073643B1 (en)	1998-04-23	2004-12-29	Dr. Reddy's Laboratories Ltd.	New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
GB9817118D0 (en) *	1998-08-07	1998-10-07	Glaxo Group Ltd	Pharmaceutical compounds
GB9914977D0 (en) *	1999-06-25	1999-08-25	Glaxo Group Ltd	Chemical compounds
EP1078923B1 (en)	1999-08-02	2006-03-08	F. Hoffmann-La Roche Ag	Process for the preparation of benzothiophene derivatives
EA200300286A1 (ru) *	2000-08-23	2003-08-28	Эли Лилли Энд Компани	Агонисты активируемых пероксисомальным пролифератором рецепторов
MXPA03010435A (es) *	2001-05-15	2004-03-09	Hoffmann La Roche	Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.

2002
- 2002-05-06 MX MXPA03010435A patent/MXPA03010435A/es active IP Right Grant
- 2002-05-06 EP EP02742955A patent/EP1392295B1/en not_active Expired - Lifetime
- 2002-05-06 DE DE60211891T patent/DE60211891T2/de not_active Expired - Lifetime
- 2002-05-06 ME MEP-2008-775A patent/ME01310B/me unknown
- 2002-05-06 PT PT02742955T patent/PT1392295E/pt unknown
- 2002-05-06 HR HR20030889A patent/HRP20030889B1/xx not_active IP Right Cessation
- 2002-05-06 CA CA002445145A patent/CA2445145C/en not_active Expired - Fee Related
- 2002-05-06 NZ NZ529033A patent/NZ529033A/en not_active IP Right Cessation
- 2002-05-06 DK DK02742955T patent/DK1392295T3/da active
- 2002-05-06 IL IL15858902A patent/IL158589A0/xx unknown
- 2002-05-06 CZ CZ20033037A patent/CZ20033037A3/cs unknown
- 2002-05-06 SK SK1385-2003A patent/SK287842B6/sk not_active IP Right Cessation
- 2002-05-06 RU RU2003134150/04A patent/RU2278859C2/ru not_active IP Right Cessation
- 2002-05-06 CN CNB028100964A patent/CN100356917C/zh not_active Expired - Fee Related
- 2002-05-06 ES ES02742955T patent/ES2264482T3/es not_active Expired - Lifetime
- 2002-05-06 PL PL367087A patent/PL208074B1/pl unknown
- 2002-05-06 JP JP2002589001A patent/JP4330883B2/ja not_active Expired - Fee Related
- 2002-05-06 SI SI200230340T patent/SI1392295T1/sl unknown
- 2002-05-06 KR KR1020037014816A patent/KR100654516B1/ko not_active Expired - Fee Related
- 2002-05-06 HU HU0400992A patent/HU230224B1/hu not_active IP Right Cessation
- 2002-05-06 BR BRPI0209821A patent/BRPI0209821B1/pt not_active IP Right Cessation
- 2002-05-06 AU AU2002342244A patent/AU2002342244B2/en not_active Ceased
- 2002-05-06 WO PCT/EP2002/004962 patent/WO2002092084A1/en not_active Ceased
- 2002-05-06 AT AT02742955T patent/ATE327753T1/de active
- 2002-05-09 US US10/142,567 patent/US6642389B2/en not_active Expired - Lifetime
- 2002-05-13 AR ARP020101739A patent/AR035892A1/es active IP Right Grant
- 2002-05-13 JO JO200242A patent/JO2282B1/en active
- 2002-05-13 MY MYPI20021726A patent/MY136761A/en unknown
- 2002-05-14 PE PE2002000399A patent/PE20021152A1/es active IP Right Grant
- 2002-05-14 EG EG2002050495A patent/EG25755A/xx active
- 2002-05-14 GT GT200200085A patent/GT200200085A/es unknown
- 2002-05-14 PA PA20028544901A patent/PA8544901A1/es unknown
2003
- 2003-10-23 IL IL158589A patent/IL158589A/en unknown
- 2003-10-31 ZA ZA2003/08538A patent/ZA200308538B/en unknown
- 2003-11-13 EC EC2003004848A patent/ECSP034848A/es unknown
- 2003-11-14 BG BG108362A patent/BG66316B1/bg unknown
- 2003-11-14 MA MA27399A patent/MA27025A1/fr unknown
- 2003-11-14 NO NO20035086A patent/NO333833B1/no not_active IP Right Cessation
2006
- 2006-08-22 CY CY20061101162T patent/CY1105160T1/el unknown
2009
- 2009-02-10 JP JP2009028181A patent/JP2009138011A/ja active Pending

Also Published As

Publication number	Publication date
CN1509173A (zh)	2004-06-30
US6642389B2 (en)	2003-11-04
KR20030096397A (ko)	2003-12-24
BR0209821A (pt)	2004-06-01
CA2445145C (en)	2008-10-14
ATE327753T1 (de)	2006-06-15
NO20035086L (no)	2003-11-14
IL158589A (en)	2010-11-30
SK287842B6 (sk)	2011-12-05
HK1067534A1 (en)	2005-04-15
JP2004529174A (ja)	2004-09-24
HU230224B1 (hu)	2015-10-28
BRPI0209821B1 (pt)	2016-09-27
JP2009138011A (ja)	2009-06-25
HRP20030889A2 (en)	2005-08-31
SK13852003A3 (en)	2004-10-05
PL367087A1 (en)	2005-02-21
RU2278859C2 (ru)	2006-06-27
AU2002342244B2 (en)	2005-06-16
RU2003134150A (ru)	2005-06-10
WO2002092084A1 (en)	2002-11-21
PA8544901A1 (es)	2003-01-24
SI1392295T1 (sl)	2006-10-31
DE60211891D1 (de)	2006-07-06
ES2264482T3 (es)	2007-01-01
HRP20030889B1 (hr)	2011-10-31
ECSP034848A (es)	2003-12-24
US20030055265A1 (en)	2003-03-20
NO333833B1 (no)	2013-09-30
JO2282B1 (en)	2005-09-12
GT200200085A (es)	2003-01-16
CA2445145A1 (en)	2002-11-21
EP1392295A1 (en)	2004-03-03
IL158589A0 (en)	2004-05-12
DE60211891T2 (de)	2007-05-24
JP4330883B2 (ja)	2009-09-16
BG108362A (bg)	2005-03-31
BG66316B1 (bg)	2013-04-30
MXPA03010435A (es)	2004-03-09
CY1105160T1 (el)	2009-11-04
EP1392295B1 (en)	2006-05-31
PT1392295E (pt)	2006-09-29
NZ529033A (en)	2005-06-24
CZ20033037A3 (cs)	2004-06-16
DK1392295T3 (da)	2006-10-02
HUP0400992A2 (hu)	2004-08-30
PE20021152A1 (es)	2003-02-07
ZA200308538B (en)	2005-04-26
AR035892A1 (es)	2004-07-21
EG25755A (en)	2012-06-26
HUP0400992A3 (en)	2007-11-28
ME01310B (me)	2011-10-10
CN100356917C (zh)	2007-12-26
KR100654516B1 (ko)	2006-12-05
MA27025A1 (fr)	2004-12-20
MY136761A (en)	2008-11-28
PL208074B1 (pl)	2011-03-31

Publication	Publication Date	Title
NO20035086L (no)	2003-11-14	Karboksylsyresubstituerte oxazolderivater for anvendelse som PPAR-alfa og gamma-aktivatorer i behandling av diabetes
NO20022467D0 (no)	2002-05-24	Substituerte oksazol- og tiazol-derivater som HPPAR-alfa- aktivatorer
NO20014409L (no)	2001-11-01	Dimere forbindelser og deres anvendelse som inhibitorer av neuraminidase
NO20022600D0 (no)	2002-05-31	Nye heterocykliske forbindelser og salter derav og medisinsk anvendelse av samme
NO20020764L (no)	2002-04-17	Benzosyrederivater for behandling av diabetes mellitus
EE200300459A (et)	2004-02-16	Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
DK1564210T3 (da)	2009-11-16	4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
DK1701946T3 (da)	2008-04-28	1-piperazin- og 1-homopiperazincarboxylatderivater, deres fremstilling og deres terapeutiske anvendelse som inhibitorer af FAAH-enzymet
PL375078A1 (en)	2005-11-14	Benzoic acid derivatives as modulators of ppar alpha and gamma
NO20052894D0 (no)	2005-06-14	4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20032388L (no)	2003-07-18	Salter av et isotiazol-4-karboksamid og anvendelse derav som anti-hyperproliferasjonsmidler
DK1617834T3 (da)	2007-02-05	Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade
EP1531806A4 (en)	2005-09-21	USE OF THIO-OXINDOLE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED DISEASES
ZA200410054B (en)	2006-02-22	Propionic acid derivatives and their use as hPPARsactivators.
AU2003279442A8 (en)	2004-04-23	2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
PL377164A1 (pl)	2006-01-23	Pochodne anilinopirazolu przydatne do leczenia cukrzycy
AU2003283597A8 (en)	2004-06-15	Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
IS7858A (is)	2005-05-23	Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)
NO20045554L (no)	2004-12-20	Fremgangsmate for behandling av diabetes
NO20054408D0 (no)	2005-09-22	3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
DK1551814T3 (da)	2008-10-27	Chirale oxazol-arylpropionsyrederivater og anvendelse deraf som ppar-agnister
DK1666473T3 (da)	2013-03-25	Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
IL169489A0 (en)	2007-07-04	Use of derivatives of succinate esters for the treatment of dementia
DK1532141T3 (da)	2010-11-22	2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
PL378197A1 (pl)	2006-03-06	Pochodne kwasów indenokarboksylowych oraz ich zastosowanie do leczenia i zapobiegania cukrzycy i dyslipidemii

Legal Events

Date	Code	Title	Description
2021-01-04	MM1K	Lapsed by not paying the annual fees